Origami Therapeutics
Developing next-generation disease-modifying protein degraders and correctors
Origami Therapeutics is a biopharmaceutical company developing small molecule protein degraders and correctors targeting neurodegenerative diseases such as Alzheimer's, Huntington's, Parkinson's, ALS, and Frontotemporal Dementia. Their proprietary ORICISION™ platform enables selective degradation of disease-causing proteins while sparing normal protein forms, leveraging the body's natural protein disposal system. The company aims to address previously 'undruggable' targets with orally administered, blood-brain barrier-penetrating small molecules.
The ORICISION™ platform discovers small molecule protein degraders and correctors that tag disease-causing proteins for removal via the body's natural disposal system, while sparing healthy protein forms.
biotech investors, researchers, and clinical partners in neurodegenerative disease
Background.
- Status
- launched
- Business model
- unknown
- Company
- Origami Therapeutics
Similar projects.
Editorial take on the space this project sits in — momentum signals, adjacent moves, our call on whether the wedge is real. Get pinged when we publish a new read or when the landscape shifts.
Have a take on this space?
Tell us what you’d build differently, where you think the incumbents miss, or what we’ve gotten wrong about this project. Comments + reactions are coming soon.